서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 30 of 30

Issue DateTitle / Author(s) / CitationFileAltmetrics
2014-03
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
DOI
2014-12
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona; Boyer, M.; Ganju, V.; Hughes, B.; Pavlakis, N.; Solomon, B.; Varma, S.; Berghmans, T.; Canon, J-L; Demedts, I.; Janssens, A.; Louis, R.; Pieters, T.; Schallier, D.; Surmont, V.; da Silva, C. Maciel; Ferreira, C-G Moreira; Hirsh, V.; Joy, A.; Laberge, F.; Morzycki, W.; Wierzbicki, R.; Han, B.; Liu, X.; Qin, S.; Shi, Y.; Wang, Y.; Wu, G.; Wu, Y-L; Zhou, C.; Ahvonen, J.; Barlesi, F.; Cadranel, J.; Dansin, E.; Fayette, J.; Morere, J-F; Moro-Sibilot, D.; Pujol, J-L; Quoix, E.; Zalcman, G.; Frickhofen, N.; Schneider, C-P; Wehler, T.; Mok, T.; So, P.; Cuffe, S.; Bearz, A.; Boni, C.; Cappuzzo, F.; Cognetti, F.; De Braud, F.; De Pas, T.; Galetta, D.; Migliorino, M.; Rocco, D.; Scagliotti, G.; Tagliaferri, P.; Tiseo, M.; Aoe, K.; Hida, T.; Kato, T.; Kozuki, T.; Nakagawa, K.; Niho, S.; Nishio, M.; Nokihara, H.; Satouchi, M.; Seto, T.; Takahashi, T.; Ahn, J-S; Kim, D-W; Kim, S-W; Berchem, G.; Rodriguez, O. Arrieta; Biesma, B.; Dingemans, A-M; Smit, E.; Helland, A.; Barata, F.; Gorbunova, V.; Manikhas, G.; Orlov, S.; Leong, S.; Lim, H-L; Soo, R.; Tan, E-H; Nosworthy, A.; Villena, M. Codes; Felip, E.; Lopez, P. Garrido; Casado, D. Isla; Banaclocha, N. Martinez; Aix, S. Ponce; Aransay, N. Reguart; Abreu, D. Rodriguez; Perez, J. Trigo; Gautschi, O.; Pless, M.; Zippelius, A.; Chang, G-C; Tsai, Y-H; Shparyk, Y.; Blackhall, F.; Steele, N.; Armenio, V.; Dragnev, K.; Dugan, M.; Gadgeel, S.; Gerber, D.; Graziano, S.; Gurubhagavatula, S.; Horn, L.; Jalal, S.; Lauer, R.; Mehra, R.; Mekhail, T.; Mirshahidi, H.; Pakkala, S.; Polikoff, J.; Raftopoulos, H.; Saleh, M.; Salgia, R.; Waqar, S.

New England Journal of Medicine, Vol.371 No.23, pp.2167-2177

DOI
2015-04
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
DOI
2016-04
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
DOI
2016-04
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
DOI
2016-04
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
DOI
2016-08
Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014
DOI
2017-04
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
DOI
2018-04
Phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer
DOI
2018-08
Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer
DOI
2018-11
Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer
DOI
2018-11
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
DOI
2019-05
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
DOI
2020-06
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
DOI
2020-11
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
DOI
2020-11
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
DOI
2021-05
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
DOI
2021-08
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer
DOI
2021-12
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
DOI
2022-09
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
DOI
2022-12
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
DOI
2022-12
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
DOI
2022-12
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
DOI
2023-04
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
DOI
2023-05
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer
DOI
2023-12
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
DOI
2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
DOI
2024-02
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
DOI
2024-06
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK plus non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
DOI
2024-10
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
DOI
1